Shundong Cang

机构：Qingdao University, Affiliated Hospital of Qingdao University, Henan Provincial People's Hospital, Zhengzhou People's Hospital, International Institute for Strategic Studies · ORCID：0000-0002-0146-7724

发表论文 181 篇 · 总被引 7798 次 · h-index 38

代表论文

• Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study (2025 · Journal of Clinical Oncology · 被引 44)
• Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC (2024 · Journal for ImmunoTherapy of Cancer · 被引 22)
• Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 13)
• HLA‐DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T‐Cell Exhaustion in HBV‐Associated Hepatocellular Carcinoma (2025 · Advanced Science · 被引 11)
• OTUD7B is a new deubiquitinase targeting p53 (2025 · Theranostics · 被引 11)
• A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001) (2025 · Journal of Hematology & Oncology · 被引 9)